(Bloomberg) -- Latigo Biotherapeutics Inc., a clinical-stage developer of non-opioid pain medicines, climbed 17% on Friday after raising $345.6 million in an upsized initial public offering, priced at the top of a marketed range.Most Read from BloombergOpenAI’s New Device Will Be Hockey Puck-Sized and Cost Over $300Iran Wants to Bar US, Israeli Ships From Hormuz in Peace AccordIran Says Agreement on Hormuz Shipping Reached With OmanTrump Administration Considers Order on Autism and VaccinesWhy D
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
HBB's Q2 revenues rise 11.6% y/y as tariff refunds boost earnings and margins, prompting an improved 2026 profit outlook.
Three of its top holdings, flash memory/data storage companies Seagate, Western Digital, and Sandisk, were among the biggest losers in the S&P 500 Friday. The stocks continued to slide following Western Digital's earnings late Wednesday, which were merely good as opposed to mind-blowingly fantastic. The memory ETF was being dragged down even more by Micron Technology and South Korean rival SK Hynix.
A single Wall Street upgrade flipped the narrative on space stocks in one session, pulling an entire sector out of its post-IPO hangover. Here is what changed and whether the buyers returning today have the fundamentals to back them up.
Diageo's FY26 earnings show resilience with cost savings and cash gains, but North America weakness pressures sales and outlook.
The tech sector is chock-full of companies with high-quality earnings growth.
Astec Industries' shares fall 10.4% in a week as earnings pressure, lower guidance and order delays weigh against backlog gains.
Airbnb (ABNB) reported stronger Q2 bookings as product changes contributed to higher revenue in the
All three major US stock indexes were up in late-morning trading Friday after the Bureau of Labor St
Rigetti Computing (RGTI) reported solid Q2 results, driven by Novera shipments and a shift toward a
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Zeta Global surges 12.9% as strong Q2 growth, higher 2026 guidance and rising AI adoption offset margin, integration and timing risks.
Can DY's acquisition strategy unlock new growth as it expands into electrical infrastructure and data center connectivity?
Cloudflare shares jumped 16% before the bell after stronger guidance.
NTGR's Q2 earnings beat estimates as Enterprise growth and wider margins offset Consumer weakness amid memory-cost headwinds.
Investors are increasingly bearish on the adtech specialist.
INTR vs. BAM: Which Stock Is the Better Value Option?
NVST vs. ABT: Which Stock Is the Better Value Option?
Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.
Wall Street expects second-quarter revenue of about $2.55 billion.
This semiconductor stock has doubled in 2026 -- and the climb may not be ending anytime soon.
NVIDIA's 11% monthly gain is backed by surging AI demand, strong cash flow and a forward P/E below the tech sector average.
Dave lost 97% of its value before a 1-for-32 reverse split. Now the fintech stock has surged back. The story is a warning to investors as SPACs mount a comeback.
DNOW's Q2 revenues surge 108% as earnings beat estimates, integration gains advanced and management raised its 2026 revenue and cash flow outlook.
First Solar and T1 Energy shares climbed after the Trump administration imposed tariffs and price floors on imported solar products to support U.S. manufacturing.
DDOG tops Q2 earnings and revenue guidance as sales rise 36%, customer expansion continues, and full-year outlook reflects a major customer's lower usage.
The firm expects memory prices to lose momentum over the next four quarters.
NET's Q2 earnings beat estimates as large-customer growth, Workers adoption and stronger execution drive 35.9% revenue growth.
Howmet is the Big Cap 20 component in focus as the stock tests a key level after breaking out in June. The stock is wading in a 5% buy zone, rendering it actionable now. Both Howmet and fellow aerospace stock ATI reported robust earnings, causing several of these names to rally in unison.
AI agents are already breaching systems and unlocking enterprise value at a pace few expected, and the next leap toward self-healing infrastructure could reshape entire industries overnight. Two software names are quietly positioning themselves to own that future before most investors even know the race has started.